Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 2019
Author(s): Piotr Ponikowski Added: 4 years ago
We are joined on site by Dr Piotr Ponikowski at HFA 2019 to discuss the management of iron deficiency in Heart Failure, and how to implement best practices to improve patient outcomes. View more

Heart Failure
AHA 22: Efficacy of Empagliflozin in Black vs White Pts With Heart Failure
Author(s): Subodh Verma Added: 1 year ago
AHA 22 - Dr Subodh Verma (St. Michael's Hospital, Toronto, CA) presents the findings of an ethnicity-focussed analysis of the EMPEROR-POOLED study, originally revealed at AHA 2022. EMPEROR-POOLED was a pooled analysis from the EMPEROR-Preserved and EMPEROR-Reduced studies, which studied the effects of empagliflozin on patients with heart failure. This sub-analysis aims to evaluate the clinical… View more

Demographic
Heart Failure in Focus - Ep 5
Author(s): Muthiah Vaduganathan , Mikhail Kosiborod Added: 1 year ago
This month we are joined by Dr Mikhail Kosiborod, clinical trialist, Professor of Medicine at St Luke’s Heart Institute and leading expert on Quality of Life (QoL) instruments worldwide.Dr Kosiborod discusses functional and QoL outcomes of foundational therapies in Heart Failure (HF) and the clinical application of this data. Additionally, we learn how scoring systems like theKansas City… View more

Heart Failure
TAVR and SAVR Outcomes in LVAD Patients with AI
Author(s): Aniket S Rali , Siva Taduru , Lena E Tran , et al Added: 1 year ago

Heart Failure
Late breaking Clinical Trial Data Addressing Cardiovascular Outcomes in Patients with Diabetes presented at American College of Cardiology Congress
Added: 1 week ago Source:  Radcliffe Cardiology, Greg Guillory
Two late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes and prior myocardial… View more
Author(s): Patrick Campbell , Selim Krim , Hector Ventura Added: 3 years ago
Heart failure remains a significant burden to the US healthcare system and contributes greatly to the morbidity and mortality of the population. The impact of an ageing population, improved survival in coronary artery disease (CAD) and adverse life-style choices will ultimately result in an increased burden on an already taxed health care system. Heart failure affects over 5 million people with… View more

Heart Failure

Prevention & Chronic Conditions
De Novo HF Versus ADCHF
Author(s): Wilson Matthew Raffaello , Joshua Henrina , Ian Huang , et al Added: 3 years ago

Heart Failure
PULSE-trial: Summarising the clinical outcomes and benefits of iVAC 2L in Clinical Practice
Author(s): Joan Antoni Gómez-Hospital Added: 2 years ago
In this video series, Professor Nicolas van Mieghem will discuss the benefits of iVAC 2L ® in clinical practice and will share the learnings and key outcomes from the Pulse Trial, and the effect of next generation pulsatile mechanical circulatory support (MCS). This video is supported by PulseCath in collaboration with their co-sponsors: CardiRad, Sanomed, LeviBio, Thomy F.E., Sonimed and… View more

Heart Failure

MI/ACS
TCT 23: Late-Breaking Clinical Trials Revealed
Added: 6 months ago Source:  Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in… View more
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 4 months ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Standards & Guidelines

Prevention & Chronic Conditions